European Commission Approves Sanofi's Sarclisa for Home Use in Multiple Myeloma

The European Commission has approved Sanofi's Sarclisa for subcutaneous administration in multiple myeloma patients. This marks the first anticancer treatment in the EU to be delivered via an on-body injector, offering patients the convenience of at-home or outpatient treatment. The approval covers all existing indications for the intravenous formulation of the drug, enhancing patient quality of life.